The Utility of the CA 19-9 Test in Patients With Pancreatic Cancer
Wen Wee Ma, MBBS, associate professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses the utility of CA 19-9 in patients with pancreatic cancer.
Clinical Pearls
Wen Wee Ma, MBBS, associate professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses the utility of CA 19-9 in patients with pancreatic cancer.
- CA 19-9 is a cancer marker that can be measured in the blood and is elevated in 60-70% of patients with pancreatic cancer
- High levels of CA 19-9 in a patient who does not otherwise have clinical features of pancreatic cancer is not helpful in obtaining a diagnosis
- CA 19-9 is primarily used in monitoring treatment response
VisitPancreatic Cancer ActionorRoswell Park Cancer Institute
Recent Videos
Related Content
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Article
Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
